Abstract | AIMS: PATIENTS AND METHODS: RESULTS: Mean serum phosphorus level at the end of washout was 2.5 +/- 0.5 mmol/l (7.7 +/- 1.5 mg/dl; n=73), and there was no evidence of a difference in levels between the treatment groups pre-randomization. At the end of the study, lanthanum carbonate-treated patients had significantly lower phosphorus levels (1.6 +/- 0.5 mmol/l [5.1 +/- 1.5 mg/dl]; n=30) than those receiving placebo (2.3 +/- 0.4 mmol/l [7.2 +/- 1.3 mg/dl]; n=31; p < 0.001). In addition, a significantly higher proportion of patients receiving lanthanum carbonate had controlled serum phosphorus levels (60%) compared with the placebo group (10%; p < 0.001). Ca x P product levels were also significantly lower in the lanthanum carbonate group at the end of randomized treatment (p < 0.001). Lanthanum carbonate was well tolerated; only one serious adverse event was reported, which was unrelated to treatment. CONCLUSIONS:
|
Authors | S S Chiang, J B Chen, W C Yang |
Journal | Clinical nephrology
(Clin Nephrol)
Vol. 63
Issue 6
Pg. 461-70
(Jun 2005)
ISSN: 0301-0430 [Print] Germany |
PMID | 15960148
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Phosphates
- lanthanum carbonate
- Lanthanum
|
Topics |
- Adult
- Aged
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Kidney Failure, Chronic
(blood, therapy)
- Lanthanum
(therapeutic use)
- Male
- Middle Aged
- Phosphates
(blood)
- Renal Dialysis
- Treatment Outcome
|